Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone844-902-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.90 million
Profitability
Miscellaneous
Employees23
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions
What is Acer Therapeutics' stock symbol?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Acer Therapeutics' earnings last quarter?
Acer Therapeutics Inc (NASDAQ:ACER) issued its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the Zacks' consensus estimate of ($0.78) by $0.31. View Acer Therapeutics' Earnings History.
When is Acer Therapeutics' next earnings date?
What price target have analysts set for ACER?
5 Wall Street analysts have issued twelve-month price targets for Acer Therapeutics' shares. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' stock price to reach $31.00 in the next year. This suggests a possible upside of 1,253.7% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.
What is the consensus analysts' recommendation for Acer Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.
What are Wall Street analysts saying about Acer Therapeutics stock?
Here are some recent quotes from research analysts about Acer Therapeutics stock:
- 1. According to Zacks Investment Research, "Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. " (5/17/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We value Acer using a composite risk-adjusted net present value (rNPV) approach, which employs a 15% discount rate and 30% effective tax rate across all future cash flows, while ascribing an 85% probability of success to EDSIVO and a 60% and 50% probability of success to MSUD, respectively. This yields a total rNPV of $600M, with $350M coming from EDSIVO and $250M from ACER-001. Assuming approximately 11M fully-diluted shares outstanding as of mid-2019, this translates into a price objective of $55.00 per share." (12/27/2018)
Has Acer Therapeutics been receiving favorable news coverage?
Media headlines about ACER stock have been trending positive on Tuesday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acer Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Acer Therapeutics.
Who are some of Acer Therapeutics' key competitors?
Some companies that are related to Acer Therapeutics include Sunesis Pharmaceuticals (SNSS), Chembio Diagnostics (CEMI), Trevi Therapeutics (TRVI), Savara (SVRA), Tiziana Life Sciences (TLSA), Catalyst Biosciences (CBIO), Merrimack Pharmaceuticals (MACK), Alpine Immune Sciences (ALPN), Aquinox Pharmaceuticals (AQXP), Relmada Therapeutics (RLMD), ASLAN PHARMACEU/ADR (ASLN), Arbutus Biopharma (ABUS), Ovid Therapeutics (OVID), Trevena (TRVN) and Selecta Biosciences (SELB).
What other stocks do shareholders of Acer Therapeutics own?
Who are Acer Therapeutics' key executives?
Acer Therapeutics' management team includes the folowing people:
- Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
- Mr. Harry S. Palmin, COO & CFO (Age 49)
- Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
- Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
- Ms. Jeannie Kim, VP of Corp. Devel.
Who are Acer Therapeutics' major shareholders?
Acer Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.29%), Vanguard Group Inc. (2.76%), Northern Trust Corp (0.48%), Wedbush Securities Inc. (0.24%), JPMorgan Chase & Co. (0.21%) and Citadel Advisors LLC (0.17%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.
Which major investors are buying Acer Therapeutics stock?
ACER stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wedbush Securities Inc., Citadel Advisors LLC, Vanguard Group Inc., Jane Street Group LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.
How do I buy shares of Acer Therapeutics?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acer Therapeutics' stock price today?
One share of ACER stock can currently be purchased for approximately $2.29.
How big of a company is Acer Therapeutics?
Acer Therapeutics has a market capitalization of $23.12 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.
What is Acer Therapeutics' official website?
How can I contact Acer Therapeutics?
Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]
MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
